« Back to news

Alba Bioscience receives Queens Award for Enterprise

Alba Bioscience receives Queens Award for Enterprise


Alba Bioscience & Queens Award for Enterprise

The award has been granted as a result of Alba Bioscience’s impressive record or strong and continuous growth in international sales over the last six years. The company, which employs 222 people over its three Edinburgh sites (Ellen’s Glen Road, Pentlands Science Park and Technopole), develops, manufactures and supplies products for the global Transfusion Diagnostics market.

Alba Bioscience Ltd trades under the name of its parent company, Quotient. Since 2010, direct sales by Quotient in to the U.S. have grown by 40% each year and sales to key original equipment manufacturer (OEM) customers in the company’s top five overseas markets (USA, France, Japan, Spain and Switzerland) have shown an annual growth rate of 27%.  

The Queen’s Awards for Enterprise are made annually by Her Majesty The Queen.  They are granted in recognition of only the highest levels of excellence demonstrated by UK-based businesses in the categories of international trade, innovation and sustainable development.

For over 30 years, Alba Bioscience/Quotient has developed and manufactured high quality products for use in Transfusion Diagnostics (characterising donor and patient blood prior to transfusion).  Quotient now offers over 40 FDA-licensed blood-grouping products for sale in the U.S.  A further 20 new blood grouping products are currently under development or in FDA review for licensing. In addition to directly serving our U.S. customers, Quotient has developed and manufactures products for other leading providers of Transfusion Diagnostics products for sale worldwide.

In December 2015 Quotient announced plans to build a new 96,000 square foot product development and manufacturing facility near Edinburgh, to support the future growth plans for its conventional reagents business and ongoing research and development (particularly for MosaiQ™, its next generation automation platform for transfusion diagnostics).  Investment in the new facility is forecast to total £15 million.

Leveraging its expertise in Transfusion Diagnostics, Quotient is developing MosaiQ™, its next generation automation platform to address the comprehensive needs of the global Transfusion Diagnostics market. Once approved for sale, MosaiQ™ will be the first fully automated solution for blood grouping, quickly and comprehensively characterising both donor and patient blood, improving patient outcomes and eliminating the need for expensive and time-consuming manual testing.  MosaiQ™ will also undertake all mandated serological disease screening tests required for donor blood.

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening,

Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania. 

Share this: